Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.
The appropriate sequencing of agents in this area is an important unanswered question. Currently, there are no head-to-head trials looking at what agents should be given in the first line.
Today, academic and community oncologists must weigh patient characteristics (pace of disease growth, tumor bulk, grade, and patient preference) and drug characteristics (method of administration and side effects) to make their decision on a first line agent.
<<< View more from NANETS